Semaglutide

Semaglutide is a synthetic version of GLP-1 (glucagon-like peptide-1), a gut hormone the body releases after eating to prompt insulin release and signal fullness. Novo Nordisk developed it as a longer-acting successor to liraglutide, and it now anchors the largest trial evidence base of any compound in its class ¹.

Two engineered changes give the molecule a working life of about one week, versus a few minutes for natural GLP-1: an amino-acid swap that blocks the DPP-4 enzyme, and a fatty-acid tail that lets it bind albumin, the main transport protein in blood ². It is sold as weekly subcutaneous injections (Ozempic for type 2 diabetes, Wegovy for weight management) and daily oral tablets (Rybelsus, oral Wegovy), with a 94% sequence match to native GLP-1 ¹.

What semaglutide is used for

Regulators have approved it for:

• Type 2 diabetes, via weekly Ozempic or daily Rybelsus ¹
• Chronic weight management in adults with obesity or overweight plus a weight-related condition, via Wegovy 2.4 mg weekly and oral Wegovy tablets ⁴⁴
• Lowering major cardiovascular events in adults with established cardiovascular disease and overweight or obesity ⁴⁷
• Slowing kidney disease in type 2 diabetes with chronic kidney disease, the first renal indication in the class ⁴⁵
• MASH (fatty liver disease with fibrosis, meaning liver scarring) under accelerated approval ⁴⁶
• Pediatric obesity from age 12 ⁴⁸

A higher-strength Wegovy HD 7.2 mg formulation extends the dose ladder for adults who tolerated 2.4 mg and need additional loss ⁴³. Investigational work has also explored semaglutide for Alzheimer's disease, Parkinson's disease prevention, antipsychotic-related weight gain, and alcohol use disorder, with mixed or early evidence ⁵.

Semaglutide works by standing in for the body's own fullness hormone. After a meal, cells in the gut lining release GLP-1 into the blood, and the hormone does three jobs at once: it tells the pancreas to release insulin, it dials down glucagon, the hormone that raises blood sugar, and it signals the brain that enough food has arrived ⁵⁴. Semaglutide mimics all three actions with a much longer presence in the bloodstream, about one week per dose rather than minutes ².

Insulin and glucose

In the insulin-producing beta cells of the pancreas, semaglutide binds the GLP-1 receptor and raises a signaling molecule called cAMP. One laboratory study found the calcium channel TRPM4 is required for this effect: without it, semaglutide cannot trigger insulin release at all ⁵³. Because the insulin boost happens only when glucose is present, the drug carries little hypoglycemia risk on its own ²⁶.

Appetite and the brain

The weight-loss effect is mostly central. Human stem-cell-derived POMC neurons, the appetite-suppressing cells in the hypothalamus, respond to semaglutide by firing more and taking in calcium through L-type channels, which is consistent with reduced hunger ⁴. The gut-brain axis amplifies the signal: enteroendocrine cells relay nutrient status to the brain through the vagus nerve, a circuit semaglutide prolongs ⁵⁴.

Semaglutide also slows the movement of food through the stomach and intestines, measured directly as delayed transit in animal studies ⁵⁵. Slower gastric emptying, stronger satiety signaling, and lower motivation for high-reward food together form the weight-loss effect ⁵⁶.

Why it lasts a week

Natural GLP-1 is destroyed within minutes by the DPP-4 enzyme. Semaglutide has an amino-acid substitution at position 8 that blocks DPP-4, plus a fatty-acid tail that lets the molecule ride on albumin, the bloodstream's transport protein. Together these give a half-life of roughly 168 hours and once-weekly dosing ².

Secondary targets

Research has documented effects beyond metabolism: improved pumping of the lymphatic vessels that drain fluid from tissues ⁴⁰, suppression of an inflammatory form of heart-cell death in sepsis models ⁵⁸, antioxidant and anti-scarring signals in diabetic kidney models ⁶⁰, and reduced markers of blood-vessel activation in a trial of people with diabetes ⁵⁷. Semaglutide crosses the blood-brain barrier only in small amounts, so many of its central effects are thought to occur at accessible brain regions or through improved metabolism ⁶.

Semaglutide's effects are documented in the largest trial programmes in the obesity and diabetes field, with randomized controlled trials corroborated by real-world registry studies ⁷.

Weight loss

• The 2.4 mg weekly subcutaneous dose produced about 14.9% to 15.2% mean body-weight loss at 68 weeks in the STEP trials, versus roughly 2.4% with placebo ¹⁰.
• The higher 7.2 mg Wegovy HD dose ranks highest among single-hormone GLP-1 therapies in network meta-analysis, at 14.66% mean loss ⁸.
• Head-to-head evidence across 10 studies and 41,381 participants shows tirzepatide, a dual GIP/GLP-1 agonist, outdoes semaglutide by about 4.3 percentage points of weight loss on average ⁷. Response varies widely: in one analysis, 21% of semaglutide-treated participants reached 15% or more weight loss by week 24, versus 44% on tirzepatide ⁶².
• Off-label dosing at 1.0 mg weekly still produced a mean 9.8% weight loss at six months in a real-world series of 20 patients ¹¹.

Blood sugar and cardiometabolic outcomes

In type 2 diabetes, real-world 12-month analyses show HbA1c, a three-month measure of average blood glucose, falling by about 0.4 points with 2.4 mg weekly, alongside weight reductions of roughly 5.5 to 5.7 kg ¹⁵. The oral combination IcoSema (semaglutide plus insulin icodec) beat daily insulin glargine on both HbA1c and weight, with fewer hypoglycemic events ¹³. Real-world 2.4 mg use was also associated with lower incident diabetes, hypertension, heart failure, and cardiovascular disease, plus a 6.2 mmHg drop in systolic blood pressure and a 4.1 kg/m² drop in BMI at 12 months ¹⁵.

Organ-level effects

• Cardiovascular risk reduction in established cardiovascular disease with obesity is a labeled indication, backed by the SELECT trial ⁴⁷.
• In obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide improves symptoms, physical limitation, and exercise capacity ¹⁷.
• The FLOW trial found reduced sustained kidney-function decline, end-stage kidney disease, and cardiovascular death in diabetes with chronic kidney disease, the basis for the renal indication ⁴⁵.
• For MASH with moderate-to-advanced fibrosis, UK consensus recommends semaglutide alongside lifestyle intervention ¹⁸.

Emerging areas

Observational data point to lower coded IBS symptoms after GLP-1 initiation ³⁹, lower alcohol use disorder incidence and recurrence ⁵², and a reduced rate of Parkinson's disease diagnosis in a Scandinavian cohort ³⁷. In Alzheimer's disease, two large phase 3 trials missed their primary endpoints at 104 weeks, though later analyses showed benefit on a measure of daily function at week 130 ⁵.

Semaglutide doses are fixed by indication rather than adjusted to body weight, with a standard four-week stepwise titration. Gastrointestinal effects cluster at initiation and after each escalation step, which is why every approved regimen starts low and climbs slowly ¹⁰.

Subcutaneous weight-management titration

The Wegovy ladder is the most used research protocol: 0.25 mg once weekly for four weeks, then 0.5, 1.0, and 1.7 mg in four-week steps, reaching the 2.4 mg maintenance dose at week 17 ¹⁰. The STEP programme reported about 14.9% mean weight loss at 68 weeks; a 7.2 mg step now extends the ladder after at least four weeks on 2.4 mg ¹⁰.

Diabetes protocols

• Subcutaneous: Ozempic starts at 0.25 mg weekly, rises through 0.5 mg and 1.0 mg, with an optional 2.0 mg step, holding at 1.0 to 2.0 mg for maintenance ¹.
• Oral: Rybelsus starts at 3 mg daily and steps monthly through 7 mg to 14 mg ².
• Oral weight management: tablets of 25 mg or 50 mg daily, taken on an empty stomach ⁴⁴.

Timing rules in the research

The weekly subcutaneous dose may be given at any time of day on a consistent weekday; the long half-life tolerates a day or two of drift ². The oral tablet is stricter: it is taken on waking with no more than 120 mL of water, at least 30 minutes before any food, drink, or other medication. The absorption enhancer SNAC, which lets the peptide cross the gut lining, fails when these fasting conditions are broken ².

Steady-state levels build over roughly four to five weeks, which is why each titration step carries a nominal one-month length ². Nausea peaks in the first 48 to 72 hours after each step up ¹⁰. Practitioner consensus holds the current step when gastrointestinal symptoms persist rather than advancing on schedule.

Community protocols sometimes split the weekly dose into two injections every three to four days to blunt gastrointestinal peaks, or micro-start at roughly 0.1 to 0.125 mg before entering the labeled ladder. These patterns are not trial-validated.

Pharmaceutical semaglutide ships ready to use. Subcutaneous products come as prefilled pens (Ozempic multidose pens, Wegovy single-dose pens) and oral products as SNAC-formulated tablets, so no reconstitution step exists in approved use ¹. Multidose pens contain phenol as a preservative; single-dose pens are preservative-free ⁸².

Research-grade lyophilized (freeze-dried) semaglutide follows standard peptide handling. Bacteriostatic water, containing 0.9% benzyl alcohol, is the standard diluent; sterile water is an alternative when benzyl alcohol is not tolerated.

Mixing is gentle by design. The diluent is added slowly down the inside wall of the vial, never shaken or vortexed, because mechanical stress aggregates peptide molecules and destroys activity. The reconstituted solution is stored refrigerated at 2 to 8°C and protected from light. Community protocols give it a practical shelf life of about 28 days with sterile water and up to 56 days with bacteriostatic water, with instructions to discard anything cloudy, discolored, or containing particles.

Freezing is prohibited after reconstitution; freeze-thaw cycles drive aggregation and activity loss ¹¹¹. Heat accelerates the same degradation, which is detectable as changes in protein structure ¹¹¹.

Compounded and falsified products

Lyophilized semaglutide sold through compounding pharmacies and gray-market channels is not bioequivalent to the approved products, and documented harms include a ten-fold dosing error requiring hospitalization and falsified vials containing insulin that caused hypoglycemic coma ³². Dose calculations for research-grade vials vary with vial size and diluent volume, so the interactive calculator in this section handles that math; verify the total milligrams per vial and the final concentration before any draw, since dosing errors concentrate at initiation and escalation ¹⁰⁰.

Medications

• Insulin and sulfonylureas. Adding semaglutide to either raises hypoglycemia risk. Case-control data identify this combination as the main driver of low blood sugar in once-weekly semaglutide users, and practice reduces the insulin and sulfonylurea doses when semaglutide is introduced ¹⁰². The fixed-dose combination IcoSema pairs semaglutide with insulin icodec in one weekly injection and produced fewer hypoglycemic events than daily insulin glargine in a phase 3b trial ¹³.
• SGLT2 inhibitors. A 24-week trial combining semaglutide with canagliflozin in early diabetic kidney disease beat either drug alone for albuminuria, HbA1c, and inflammatory markers ⁶⁹.
• Oral medications. Slowed gastric emptying can delay or destabilize absorption of narrow-therapeutic-index drugs like levothyroxine, warfarin, and digoxin during the first weeks and after each escalation step. Practice separates their dosing in time and monitors drug levels ²⁶.
• Oral contraceptives. Absorption may dip transiently during the early weeks for the same reason.
• Anesthesia. The FDA label warns of residual stomach contents and pulmonary aspiration during general anesthesia or deep sedation, even after fasting, so protocols hold the weekly dose for a week or more before elective procedures ³¹.

Peptide and combination interactions

• GLP-1 receptor agonists are not combined with each other. Semaglutide plus tirzepatide, liraglutide, or dulaglutide would share one receptor pathway and multiply gastrointestinal effects with no efficacy data ¹⁰³.
• CagriSema is the designed exception: semaglutide plus cagrilintide, a long-acting amylin analog. The two receptors sit on largely distinct neuron populations in the brainstem and produce additive feeding suppression ⁵⁶. In network meta-analysis, CagriSema reached 17.84% mean weight loss versus 14.66% for semaglutide 7.2 mg ⁸.
• Adding native GIP by infusion to semaglutide produced no additional glycemic or weight benefit in a six-week trial ¹¹⁰.
• Community protocols sometimes pair semaglutide with BPC-157 during titration for gastrointestinal tolerance; no interaction data exists, and no conflict is expected.

Supplements

Protein and fiber supplementation is common because delayed transit worsens constipation. A pilot trial found one to two plant-based high-protein shakes per day raised protein and fiber intake in GLP-1 users, with reductions in bloating and constipation ¹⁰⁹. In an animal model, co-administered ketone esters blunted semaglutide-induced skeletal muscle loss ⁸⁹. Fluid and electrolyte replacement is emphasized during titration when vomiting or diarrhea is persistent ²⁶.

Semaglutide is studied and approved as continuous chronic therapy, not a fixed course. No randomized trial has tested deliberate on-and-off cycling, and the evidence is blunt about what happens when the drug stops: in the STEP 4 trial, participants switched to placebo regained 6.9% of their body weight within a year, while those who stayed on the drug continued losing ⁶⁵. Most lost weight returns after discontinuation ⁵⁰.

Why breaks are discussed

The practical driver is gastrointestinal tolerance, which tracks circulating semaglutide exposure rather than receptor fatigue. There is no evidence that time off the drug resensitizes the GLP-1 receptor itself ⁶¹. Hair shedding, seen most strongly with semaglutide and tirzepatide, is the other common trigger; the pattern fits telogen effluvium from rapid weight loss, and slowing the dose is the usual response ²⁷.

Patterns seen in practice

• Maintenance de-escalation. After reaching goal weight, step down about one dose level per month to the lowest dose that holds weight stable. A 1.0 mg weekly dose still produced a mean 9.8% loss at six months in an observational series ¹¹.
• Low-dose holidays. Community protocols describe 12 to 16 weeks at an effective dose, then three to four weeks at a reduced step (0.25 to 0.5 mg) before resuming.
• Block cycling. Practitioner consensus describes 10 to 12 weeks at an effective dose, a four-to-eight-week full stop, then restart at 0.25 mg with full re-titration.
• Incretin rotation. Some practices alternate six-to-twelve-month blocks of semaglutide and tirzepatide, since tirzepatide produces about 4.3 percentage points more weight loss in head-to-head data ⁷.

Any gap of two weeks or more, roughly two half-lives, drops circulating exposure enough that protocol practice is to restart at 0.25 mg and re-titrate. Real-world persistence is the limiting fact: about half of users are still on treatment at one year, with a median duration around eight months ⁷⁶.

Most peptide stacking has no evidence base for semaglutide, and one rule is firm: GLP-1 receptor agonists are not combined with each other. Semaglutide plus tirzepatide, liraglutide, or dulaglutide would occupy the same receptor pathway, multiply gastrointestinal and motility effects, and has no supporting efficacy data; research practice is to switch, not stack ¹⁰³.

Combinations with trial evidence

• CagriSema (semaglutide plus cagrilintide). A designed co-agonist pairing: cagrilintide's amylin/calcitonin receptors sit on largely distinct brainstem neurons from GLP-1 receptors, producing additive suppression of both homeostatic feeding and the motivation to eat palatable food ⁵⁶. Network meta-analysis ranks CagriSema at 17.84% mean weight loss, ahead of semaglutide 7.2 mg at 14.66%, with gastrointestinal side effects rising with treatment intensity ⁸.
• IcoSema (semaglutide plus insulin icodec). A fixed weekly combination for type 2 diabetes that beat daily insulin glargine on HbA1c, weight, and hypoglycemia ¹³.
• Semaglutide plus canagliflozin. The SGLT2 inhibitor pairing outperformed either drug alone in early diabetic kidney disease across albuminuria, glycemic, and inflammatory endpoints ⁶⁹.
• Semaglutide plus GIP. A six-week infusion of native GIP added to semaglutide produced no additional glycemic or weight change, arguing against GIP add-ons outside dual-receptor molecules like tirzepatide ¹¹⁰.

Community-adjacent adjuncts

Practitioner and community protocols pair semaglutide with BPC-157 to ease gastrointestinal symptoms during titration; no interaction data exists and no conflict is expected, so this is empiric rather than evidence-based. Co-administered ketone esters blunted semaglutide-induced muscle loss in rodents ⁸⁹, and plant-based protein shakes improved protein intake and gastrointestinal symptoms in a pilot study of GLP-1 users ¹⁰⁹.

Overlapping appetite-suppressive peptides such as tesamorelin, MOTS-c, or AOD-9604 are generally avoided in the absence of safety data ¹⁰³. Sequential incretin therapy is the studied alternative to stacking: case reports describe retatrutide, then semaglutide, then dulaglutide used one after another across treatment phases in complex obesity, producing profound cumulative loss ⁴¹.

United States

Semaglutide is FDA-approved and prescription-only, with no controlled-substance scheduling documented. Wegovy 2.4 mg was approved in 2021 for chronic weight management in adults with a BMI of 30 or above, or 27 with a weight-related comorbidity ⁵⁰. Later indications followed: cardiovascular risk reduction in established cardiovascular disease (2024) ⁴⁷, pediatric obesity from age 12 (2023) ⁴⁸, and MASH with fibrosis under accelerated approval (2025) ⁴⁶. Wegovy HD 7.2 mg is approved as a step-up strength ⁴³. Ozempic holds the first renal indication for type 2 diabetes with chronic kidney disease (2025) ⁴⁵, and oral Wegovy became the first oral GLP-1 receptor agonist approved for weight management ⁴⁴.

Compounded semaglutide exists in a regulatory gray zone. The FDA authorized compounding during shortages but stated that salt forms (semaglutide sodium and acetate) are not the approved active ingredient, limiting compounding to the base form ⁷⁹. Counterfeit Ozempic warnings and falsified vials containing insulin are documented ³².

International

• European Union. Ozempic was authorized through the EMA in February 2018, and Wegovy followed for obesity in 2022 ¹. The EMA safety committee opened a 2023 review of suicidal ideation and self-harm reports across the GLP-1 class ¹²¹.
• United Kingdom. NICE recommends Wegovy for up to two years within NHS weight services, and GPs are told not to prescribe it for the cardiovascular indication without a funding guarantee ⁴⁹. The MHRA has approved oral semaglutide tablets for weight loss ¹²⁰.
• India. Wegovy launched in June 2025, with monthly pricing of about ₹17,000 to 26,000 limiting access ¹²³.

Sports

Practitioner consensus holds that semaglutide is not placed in any WADA prohibited category and is not a performance-enhancing agent of abuse. Athletes treating diabetes or obesity generally do not require a therapeutic use exemption for genuine medical use, though current WADA lists should be verified before competition.

The common pattern

Gastrointestinal side effects dominate and are dose-dependent. Pooled trial data put nausea at up to roughly 20%, diarrhea at up to 13%, constipation around 7%, and vomiting around 6%; fewer than 15% of participants stopped because of adverse events ¹⁰. Slow four-week titration minimizes these effects, which attenuate over time ⁶⁵. Rapid responders have more gastrointestinal and hepatobiliary events, though completion rates stay similar ⁶².

Documented warnings

• Thyroid. Rodent C-cell tumor findings carry a boxed warning against use with a personal or family history of medullary thyroid carcinoma or MEN2. Across pooled trials, thyroid cancer incidence stayed under 1% ²⁵.
• Eyes. A pharmacovigilance signal ties semaglutide to nonarteritic anterior ischemic optic neuropathy (NAION), a rare form of sudden vision loss, reported disproportionately with Wegovy (ROR 74.89) and Ozempic (18.81), stronger in men ²⁴. Case reports link it to rapid weight loss and dose escalation ²³.
• Pancreas and bile. Real-world weight-loss users show higher rates of pancreatitis (HR 9.09), gastroparesis (HR 3.67), and bowel obstruction (HR 4.22) than bupropion-naltrexone users, though absolute rates stay low ²⁶. Gallstone-related pancreatitis after dose escalation is reported ⁸⁵.
• Hypoglycemia. Rare on semaglutide alone; risk concentrates with insulin or sulfonylurea co-therapy, dosing errors, or falsified products, including a counterfeit vial containing insulin that caused hypoglycemic coma ²⁶.
• Anesthesia. The FDA label warns of residual stomach contents and pulmonary aspiration during anesthesia or deep sedation even when fasting ³¹.
• Mental health. Pooled analyses show no significant increase in depression (RR 1.25) or anxiety, but pharmacovigilance databases show elevated reporting of depressed mood and suicidal thoughts, with a median onset around 96 days and clustering in antidepressant users ¹⁹. Early monitoring in treatment is widely recommended.

Other signals

Rapid weight loss brings telogen-effluvium hair shedding, usually reversible ²⁷, and facial fat loss that tracks overall weight loss rather than the drug itself ⁹⁷. Lean muscle loss is documented; practice mitigates it with protein targets and resistance training, and ketone esters blunted it in an animal model ⁸⁹. Rodent studies show mild bone-remodeling suppression, while human diabetes data associate semaglutide with lower major osteoporotic fracture risk ²⁹. Postmenopausal bleeding after dose escalation and improved ovulation, which raises unplanned pregnancy risk during rapid weight loss, are reported ²¹. A single accidental 9.6 mg dose caused self-limited burning sensations lasting about a week ²²; most poison-center calls are initiation-related dosing errors ¹⁰⁰.